Step 1 topics → Immunology → Complement Deficiencies

Complement Deficiencies

USMLE Step 1 trap: Confuses hereditary angioedema with allergic angioedema, missing the bradykinin (not histamine) mechanism. Hereditary angioedema is caused by C1-inhibitor deficiency, leading to uncontrolled bradykinin generation (not histamine), which is why it does not respond to antihistamines or epinephrine.

Complement deficiencies are a high-yield immunology topic where USMLE Step 1 tests your ability to match specific complement components with their clinical consequences. The exam doesn't just ask you to memorize which protein is missing — it presents a clinical vignette and expects you to work backward from the infection pattern, lab findings, or drug history to identify the defect. The four main scenarios tested are: C1-inhibitor deficiency (hereditary angioedema), C3 deficiency (severe encapsulated bacterial infections + immune complex disease), terminal complement/MAC deficiency (Neisseria-specific susceptibility), and PNH (GPI anchor loss causing hemolysis).

What makes this topic tricky is that students conflate concepts that superficially look similar. Hereditary angioedema gets confused with allergic angioedema because both cause swelling — but the mechanism is completely different (bradykinin vs. histamine), and this matters because the treatments diverge sharply. C3 deficiency and MAC deficiency both sound like 'complement problems that cause infections,' so students lump them together and miss that Neisseria susceptibility is specifically a terminal complement problem. PNH trips people up because it's framed as a complement problem, but it's actually a mutation in a GPI anchor synthesis gene — the complement proteins themselves are normal.

For USMLE Step 1, pay special attention to ACE inhibitor contraindications in hereditary angioedema and eculizumab's mechanism in PNH — these are classic application-level questions where knowing the mechanism lets you reason through an answer you might not have memorized explicitly.

From real student decks
81%have cards covering this topic
54%have mature cards

Common misconceptions

Common mistake
Wrong: Hereditary angioedema is caused by IgE-mediated mast cell degranulation like allergic angioedema.
Right: Hereditary angioedema is caused by C1-inhibitor deficiency, leading to uncontrolled bradykinin generation (not histamine), which is why it does not respond to antihistamines or epinephrine.
Allergic angioedema is IgE-mediated mast cell degranulation releasing histamine, which is why it responds to antihistamines and epinephrine. Hereditary angioedema involves no IgE and no histamine — C1-inhibitor normally suppresses the contact activation pathway, and without it, kallikrein runs unchecked and cleaves kininogen into bradykinin. Bradykinin causes vascular leak, but antihistamines and epinephrine do nothing against bradykinin, so giving those in HAE is both ineffective and dangerous. The correct treatments are C1-INH concentrate, icatibant (bradykinin B2 receptor antagonist), or fresh frozen plasma.
Common mistake
Wrong: C3 deficiency and terminal complement (MAC) deficiency cause the same infection pattern.
Right: C3 deficiency causes severe recurrent infections with encapsulated bacteria (S. pneumoniae, H. influenzae) and immune complex disease, while MAC (C5–C9) deficiency specifically predisposes to recurrent Neisseria (meningitidis and gonorrhoeae) infections.
C3 is the convergence point of all three complement pathways and opsonizes bacteria for phagocytosis — losing C3 means losing opsonization, which devastates defense against all encapsulated bacteria and also impairs immune complex clearance (causing SLE-like disease). MAC (C5–C9) has a narrower job: forming the pore that lyses gram-negative bacteria with thin outer membranes. Neisseria species are uniquely dependent on MAC-mediated lysis for clearance, which is why MAC deficiency almost exclusively predisposes to Neisseria — not to pneumococcus or H. flu. These two defects have completely different infection profiles, and the exam will present vignettes designed to make you choose between them.
Common mistake
Wrong: PNH is caused by a complement protein deficiency.
Right: PNH is caused by a somatic PIGA mutation that prevents GPI anchor synthesis, leaving RBCs without CD55 and CD59 (complement regulatory proteins), making them susceptible to MAC-mediated lysis.
PNH is not a deficiency of a complement protein — C3, C5, and all the others are present and functional. The problem is that RBCs in PNH lack CD55 (decay-accelerating factor) and CD59 (protectin), two proteins that normally sit on the RBC surface and brake complement activation. These proteins are attached to the membrane via GPI anchors, and in PNH, a somatic mutation in PIGA disrupts GPI anchor synthesis. Without CD55 and CD59, complement runs uncontrolled on the RBC surface and MAC lyses the cell. Eculizumab blocks C5 cleavage, preventing MAC formation and protecting the unanchored RBCs.
Common mistake
Gap: Missing ACE inhibitor contraindication in hereditary angioedema due to bradykinin accumulation
ACE inhibitors are contraindicated in hereditary angioedema because they block bradykinin degradation, worsening the bradykinin-mediated swelling that defines the condition.
ACE (angiotensin-converting enzyme) does double duty: it converts angiotensin I to angiotensin II, but it also degrades bradykinin. When you give an ACE inhibitor, bradykinin accumulates — this is why ACE inhibitors cause cough and can cause angioedema as a side effect even in normal patients. In a patient with hereditary angioedema who already has uncontrolled bradykinin generation, an ACE inhibitor removes the one degradation pathway that keeps bradykinin in check, and it can trigger life-threatening laryngeal swelling. This is a high-yield contraindication that the exam loves to embed in a medication reconciliation vignette.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Recognize the clinical features of hereditary angioedema (recurrent non-pitting, non-pruritic swelling without urticaria), understand that it is bradykinin-mediated rather than histamine-mediated, and identify which drugs are contraindicated (ACE inhibitors, estrogen-containing OCPs) and why.
  2. Predict the infection pattern in C3 deficiency — recurrent severe infections with encapsulated organisms (S. pneumoniae, H. influenzae, N. meningitidis) and susceptibility to immune complex disease — and distinguish this from other complement defects.
  3. Identify that deficiency in terminal complement components C5–C9 (the MAC) specifically predisposes patients to recurrent Neisseria infections (N. meningitidis and N. gonorrhoeae), and recognize that this is the one infection pattern tied to late complement defects.
  4. Explain the mechanism of PNH: a somatic PIGA mutation prevents GPI anchor synthesis, stripping RBCs of CD55 and CD59, leaving them unprotected from MAC-mediated lysis, and understand why eculizumab (anti-C5 antibody) is the treatment.

Can you avoid these mistakes?

A 28-year-old woman has recurrent episodes of lip and tongue swelling without urticaria or pruritus. She takes an oral contraceptive. Labs show low C4 between attacks and normal C3. Epinephrine during a prior attack had no effect. What is the mechanism of her condition, and which medication she is currently taking should be discontinued?
A 19-year-old college student presents with his third episode of meningococcal meningitis. His immunoglobulin levels and neutrophil count are normal. Which complement component(s) are most likely deficient, and why does this deficiency specifically predispose to Neisseria rather than Streptococcus pneumoniae?
A patient with a history of aplastic anemia now presents with episodic dark morning urine, fatigue, and a new DVT. Flow cytometry shows a RBC population lacking CD55 and CD59. Complement proteins C3 and C5 are detectable in serum. What is the mechanism linking the PIGA mutation to RBC lysis, and what drug targets this pathway?
A patient with known C3 deficiency asks whether their infection risk is similar to a friend with a late complement deficiency (C8 deficiency). How would you explain the difference in their susceptibility — both in terms of which organisms threaten each patient and why?

Related topics

Complement Functions and Regulation Thymus and T Cell Maturation Spleen Architecture and Function Lymph Node and MALT Architecture Innate Immune Cells Overview

See how your Anki deck covers this topic.

Upload your deck for a free audit →